Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
197 participants
INTERVENTIONAL
2020-09-01
2024-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection
NCT01090232
Seroprevalence Hepatitis E Infection in Healthy Blood Donors
NCT03601221
Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors
NCT06457438
Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants
NCT02366286
HELIO Liver Test Performance Study in China (HEPATIC)
NCT05053412
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oncological disease
Serum was taken from each patient before treatment initiation and during treatment follow-up. In addition, oncological participants completed a questionnaire consisting of eight questions focusing on quantitative aspects, to identify risk factors for HEV infection.
ELISA testing
Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
Healthy controls
Serum samples were analysed retrospectively using HEV ELISAs
ELISA testing
Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
Control hospitalized due to SARS-CoV-2 infection
Serum samples were analysed retrospectively using HEV ELISAs
ELISA testing
Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELISA testing
Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* not given written consent
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medizinische Hochschule Brandenburg Theodor Fontane
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Isabel-Elena Haller
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabel-Elena Haller
Role: PRINCIPAL_INVESTIGATOR
Medical School (MHB) Theodor Fontane
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical School (MHB) Theodor Fontane
Brandenburg, Brandenburg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HepE-Onko-BB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.